Literature DB >> 18278580

Protein-DNA array-based identification of transcription factor activities differentially regulated in skeletal muscle of normal and dystrophin-deficient mdx mice.

Charu Dogra1, Daya Shankar Srivastava, Ashok Kumar.   

Abstract

Inactivation of dystrophin gene is the primary cause of Duchenne muscular dystrophy (DMD) in humans and mdx mice. However, the underpinning mechanisms, which govern the pathogenesis of dystrophin-deficient skeletal muscle, remain poorly understood. We have previously reported activation of mitogen-activated protein kinases (MAPK), nuclear factor-kappa B (NF-kappaB), and phosphatidyl-inositol 3-kinase/Akt (PI3K/Akt) signaling pathways in diaphragm muscle of mdx mice. In this study, using a protein-DNA array-based approach, we have investigated the activation of 345 transcription factors in diaphragm muscle of 6-week old normal and dystrophin-deficient mdx mice. Our data demonstrate increased activation of a number nuclear transcription factors including AP1, HFH-3, PPARalpha, c.myb BP, ETF, Fra-1/JUN, kBF-A, N-rasBP, lactoferrin BP, Myb(2), EBP40_45, EKLF(1), p53(2), TFEB, Myc-Max; c-Rel; E2, ISRE; NF-kB; Stat1 p84/p91, Antioxidant RE, EVI-1, Stat3, AP3, p53, Stat4, AP4, HFH-1, FAST-1, Pax-5, and Beta-RE in the diaphragm muscle of mdx mice compared to corresponding normal mice. The level of activation for p53 was highest among all the transcription factors studied. Furthermore, higher activation of p53 in diaphragm muscle of mdx mice was associated with its increased phosphorylation and nuclear translocation. Collectively, our data suggest that the primary deficiency of dystrophin leads to the aberrant activation of nuclear transcription factors which might further contribute to muscle pathogenesis in mdx mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18278580      PMCID: PMC2785438          DOI: 10.1007/s11010-008-9716-6

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  47 in total

1.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

2.  Transcription factors: important tools and targets for molecular medicine.

Authors:  C Scheidereit
Journal:  J Mol Med (Berl)       Date:  1996-12       Impact factor: 4.599

Review 3.  Muscular dystrophies and the dystrophin-glycoprotein complex.

Authors:  V Straub; K P Campbell
Journal:  Curr Opin Neurol       Date:  1997-04       Impact factor: 5.710

4.  Dystrophin: the protein product of the Duchenne muscular dystrophy locus.

Authors:  E P Hoffman; R H Brown; L M Kunkel
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

5.  Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle.

Authors:  J M Ervasti; K Ohlendieck; S D Kahl; M G Gaver; K P Campbell
Journal:  Nature       Date:  1990-05-24       Impact factor: 49.962

6.  Prednisolone decreases cellular adhesion molecules required for inflammatory cell infiltration in dystrophin-deficient skeletal muscle.

Authors:  Michelle Wehling-Henricks; James J Lee; James G Tidball
Journal:  Neuromuscul Disord       Date:  2004-09       Impact factor: 4.296

7.  p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1.

Authors:  Jan Bohuslav; Lin-Feng Chen; Hakju Kwon; Yajun Mu; Warner C Greene
Journal:  J Biol Chem       Date:  2004-04-08       Impact factor: 5.157

8.  Participation of p53 protein in the cellular response to DNA damage.

Authors:  M B Kastan; O Onyekwere; D Sidransky; B Vogelstein; R W Craig
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

9.  Transcription of the dystrophin gene in human muscle and non-muscle tissue.

Authors:  J Chelly; J C Kaplan; P Maire; S Gautron; A Kahn
Journal:  Nature       Date:  1988-06-30       Impact factor: 49.962

10.  Animal models for muscular dystrophy show different patterns of sarcolemmal disruption.

Authors:  V Straub; J A Rafael; J S Chamberlain; K P Campbell
Journal:  J Cell Biol       Date:  1997-10-20       Impact factor: 10.539

View more
  16 in total

1.  Systemic delivery of NEMO binding domain/IKKγ inhibitory peptide to young mdx mice improves dystrophic skeletal muscle histopathology.

Authors:  Daniel P Reay; Michele Yang; Jon F Watchko; Molly Daood; Terrence L O'Day; Khaleel K Rehman; Denis C Guttridge; Paul D Robbins; Paula R Clemens
Journal:  Neurobiol Dis       Date:  2011-05-23       Impact factor: 5.996

2.  Increased resting intracellular calcium modulates NF-κB-dependent inducible nitric-oxide synthase gene expression in dystrophic mdx skeletal myotubes.

Authors:  Francisco Altamirano; Jose R López; Carlos Henríquez; Tadeusz Molinski; Paul D Allen; Enrique Jaimovich
Journal:  J Biol Chem       Date:  2012-05-01       Impact factor: 5.157

3.  Transcriptomic analysis of dystrophin RNAi knockdown reveals a central role for dystrophin in muscle differentiation and contractile apparatus organization.

Authors:  Mohammad M Ghahramani Seno; Capucine Trollet; Takis Athanasopoulos; Ian R Graham; Pingzhao Hu; George Dickson
Journal:  BMC Genomics       Date:  2010-06-01       Impact factor: 3.969

4.  Use of pifithrin to inhibit p53-mediated signalling of TNF in dystrophic muscles of mdx mice.

Authors:  Felicity J Waters; Thea Shavlakadze; Matthew J McIldowie; Matthew J Piggott; Miranda D Grounds
Journal:  Mol Cell Biochem       Date:  2009-10-27       Impact factor: 3.396

5.  Genome-wide gene expression in a patient with 15q13.3 homozygous microdeletion syndrome.

Authors:  Jean-Baptiste Le Pichon; Shihui Yu; Nataliya Kibiryeva; William D Graf; Douglas C Bittel
Journal:  Eur J Hum Genet       Date:  2013-01-30       Impact factor: 4.246

6.  Distinct roles of TRAF6 at early and late stages of muscle pathology in the mdx model of Duchenne muscular dystrophy.

Authors:  Sajedah M Hindi; Shuichi Sato; Yongwon Choi; Ashok Kumar
Journal:  Hum Mol Genet       Date:  2013-10-24       Impact factor: 6.150

7.  Novel approach to meta-analysis of microarray datasets reveals muscle remodeling-related drug targets and biomarkers in Duchenne muscular dystrophy.

Authors:  Ekaterina Kotelnikova; Maria A Shkrob; Mikhail A Pyatnitskiy; Alessandra Ferlini; Nikolai Daraselia
Journal:  PLoS Comput Biol       Date:  2012-02-02       Impact factor: 4.475

8.  Sphingosine-1-phosphate enhances satellite cell activation in dystrophic muscles through a S1PR2/STAT3 signaling pathway.

Authors:  Kenneth C Loh; Weng-In Leong; Morgan E Carlson; Babak Oskouian; Ashok Kumar; Henrik Fyrst; Meng Zhang; Richard L Proia; Eric P Hoffman; Julie D Saba
Journal:  PLoS One       Date:  2012-05-14       Impact factor: 3.240

9.  Unveiling transcription factor regulation and differential co-expression genes in Duchenne muscular dystrophy.

Authors:  Lijun Tian; Junhua Cao; Xingqiang Deng; Chuanling Zhang; Tong Qian; Xianxiang Song; Baoshan Huang
Journal:  Diagn Pathol       Date:  2014-10-23       Impact factor: 2.644

10.  ZASP interacts with the mechanosensing protein Ankrd2 and p53 in the signalling network of striated muscle.

Authors:  Valentina C Martinelli; W Buck Kyle; Snezana Kojic; Nicola Vitulo; Zhaohui Li; Anna Belgrano; Paolo Maiuri; Lawrence Banks; Matteo Vatta; Giorgio Valle; Georgine Faulkner
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.